Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study

Improved efficacy of concurrent anti-PD1 antibody plus AVD versus ABVD in patients with newly diagnosed early unfavorable and advanced stage classic Hodgkin lymphoma: a retrospective matched cohort study

Abstract Background The prognosis of early unfavorable and advanced stage classic Hodgkin lymphoma (cHL) remains suboptimal with the widely used ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) regimen. Novel agents such as brentuximab vedotin (BV) and anti-PD-1 antibody have demonstrated...

Full description

Saved in:
Bibliographic Details
Main Authors: Mengqiu Wu, Peng Sun, Baitian Zhao, Hang Yang, Yi Xia, Man Nie, Qingqing Cai, Huiqiang Huang, He Huang, Zhongjun Xia, Yu Wang, Zhiming Li, Panpan Liu
Format: Article
Language:English
Published: Springer 2025-05-01
Series:Cancer Immunology, Immunotherapy
Subjects:
Lymphoma
Immune checkpoint inhibitor
Chemotherapy
Modified progression-free survival
Complete response
Online Access:https://doi.org/10.1007/s00262-025-04041-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00262-025-04041-z

Similar Items